IVI RMA Global and Conceivable Life Sciences Collaborate to Revolutionize IVF with First Automated Lab
In a groundbreaking move for reproductive medicine, IVI RMA Global, recognized as a premier fertility care organization globally, has announced a strategic partnership with Conceivable Life Sciences. This collaboration is aimed at revolutionizing the landscape of in vitro fertilization (IVF) by deploying the first automated IVF laboratory in the United States through Conceivable’s innovative AURA™ platform, slated to launch in 2027.
The landmark partnership combines the expertise of two organizations that are at the forefront of fertility care and technology. IVI RMA Global has been a leading force in the fertility industry, known for its commitment to improving patient outcomes and delivering personalized care. Conceivable Life Sciences is a pioneering company specializing in robotics and artificial intelligence applications within clinical IVF settings.
As the first major fertility network to adopt Conceivable’s cutting-edge technology, IVI RMA aims to establish a new benchmark in fertility care that is more precise, consistent, and accessible for patients worldwide. The integration of the AURA platform marks a significant advancement, representing the first instance where automation is introduced in an IVF laboratory to enhance the work of embryologists rather than replace it.
Professor Antonio Pellicer, Executive Chairman of IVI RMA Global, expressed his enthusiasm for this partnership, stating, "By integrating platforms like AURA into our laboratory ecosystem, we are not only enhancing our patients’ capabilities to build families but also showcasing how advanced technology can complement the expertise of embryologists and clinicians. Our history demonstrates IVI RMA's ongoing commitment to defining the future of reproductive medicine, and this collaboration is a pivotal step in that journey."
The AURA platform is designed to function seamlessly within a clinical environment, automating numerous manual, operator-dependent processes with machine-like precision. This technological evolution is currently undergoing pilot studies involving over 100 patients and the processing of more than 1,000 eggs, leading to successful live births. This level of standardization and refinement in the laboratory setting is expected to significantly enhance the quality of embryo development and ultimately patient success rates.
Lynn Mason, CEO of IVI RMA North America, emphasized the potential impact of this partnership, highlighting the mission to improve accessibility and consistency in fertility care. "Every patient visiting an IVF clinic deserves the same high-quality care, regardless of the clinic's location. This partnership with Conceivable embarks on a journey toward offering unprecedented quality across all clinics, making personalized and effective fertility treatments more universally accessible."
Conceivable’s CEO, Alan Murray, shared similar sentiments, viewing this collaboration not merely as a business venture but as a defining moment for the future of reproductive medicine. He noted, "We have the chance to bridge the gap between the best available care in elite clinics and the broader patient population needing these services. This partnership sets a new standard for IVF laboratory performance and patient outcomes."
IVI RMA has also made a strategic investment in Conceivable as part of this collaboration, further illustrating a commitment to advancing technology that enhances infertility treatment. The deployment of the AURA robotic platform in the United States will pave the way for similar expansions throughout IVI RMA’s network in Europe, Latin America, and the Middle East, broadening access to cutting-edge fertility care for a more extensive patient base.
In essence, this partnership signifies a significant shift towards a future where reproductive medicine is enhanced through the synergy of human expertise and technological innovation. As IVI RMA and Conceivable Life Sciences push the boundaries of what is possible in fertility, they aim to instill confidence in patients navigating their fertility journeys, empowering families to achieve successful outcomes. This exciting intersection of innovation and compassion in reproductive health care stands to transform the IVF landscape for years to come.
The landmark partnership combines the expertise of two organizations that are at the forefront of fertility care and technology. IVI RMA Global has been a leading force in the fertility industry, known for its commitment to improving patient outcomes and delivering personalized care. Conceivable Life Sciences is a pioneering company specializing in robotics and artificial intelligence applications within clinical IVF settings.
As the first major fertility network to adopt Conceivable’s cutting-edge technology, IVI RMA aims to establish a new benchmark in fertility care that is more precise, consistent, and accessible for patients worldwide. The integration of the AURA platform marks a significant advancement, representing the first instance where automation is introduced in an IVF laboratory to enhance the work of embryologists rather than replace it.
Professor Antonio Pellicer, Executive Chairman of IVI RMA Global, expressed his enthusiasm for this partnership, stating, "By integrating platforms like AURA into our laboratory ecosystem, we are not only enhancing our patients’ capabilities to build families but also showcasing how advanced technology can complement the expertise of embryologists and clinicians. Our history demonstrates IVI RMA's ongoing commitment to defining the future of reproductive medicine, and this collaboration is a pivotal step in that journey."
The AURA platform is designed to function seamlessly within a clinical environment, automating numerous manual, operator-dependent processes with machine-like precision. This technological evolution is currently undergoing pilot studies involving over 100 patients and the processing of more than 1,000 eggs, leading to successful live births. This level of standardization and refinement in the laboratory setting is expected to significantly enhance the quality of embryo development and ultimately patient success rates.
Lynn Mason, CEO of IVI RMA North America, emphasized the potential impact of this partnership, highlighting the mission to improve accessibility and consistency in fertility care. "Every patient visiting an IVF clinic deserves the same high-quality care, regardless of the clinic's location. This partnership with Conceivable embarks on a journey toward offering unprecedented quality across all clinics, making personalized and effective fertility treatments more universally accessible."
Conceivable’s CEO, Alan Murray, shared similar sentiments, viewing this collaboration not merely as a business venture but as a defining moment for the future of reproductive medicine. He noted, "We have the chance to bridge the gap between the best available care in elite clinics and the broader patient population needing these services. This partnership sets a new standard for IVF laboratory performance and patient outcomes."
IVI RMA has also made a strategic investment in Conceivable as part of this collaboration, further illustrating a commitment to advancing technology that enhances infertility treatment. The deployment of the AURA robotic platform in the United States will pave the way for similar expansions throughout IVI RMA’s network in Europe, Latin America, and the Middle East, broadening access to cutting-edge fertility care for a more extensive patient base.
In essence, this partnership signifies a significant shift towards a future where reproductive medicine is enhanced through the synergy of human expertise and technological innovation. As IVI RMA and Conceivable Life Sciences push the boundaries of what is possible in fertility, they aim to instill confidence in patients navigating their fertility journeys, empowering families to achieve successful outcomes. This exciting intersection of innovation and compassion in reproductive health care stands to transform the IVF landscape for years to come.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.